Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A.
Mouron S, Bueno MJ, Lluch A, Manso L, Calvo I, Cortes J, Garcia-Saenz JA, Gil-Gil M, Martinez-Janez N, Apala JV, Caleiras E, Ximénez-Embún P, Muñoz J, Gonzalez-Cortijo L, Murillo R, Sánchez-Bayona R, Cejalvo JM, Gómez-López G, Fustero-Torre C, Sabroso-Lasa S, Malats N, Martinez M, Moreno A, Megias D, Malumbres M, Colomer R, Quintela-Fandino M. Mouron S, et al. Nat Commun. 2022 Dec 7;13(1):7529. doi: 10.1038/s41467-022-35065-z. Nat Commun. 2022. PMID: 36477027 Free PMC article.
Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.
Manso L, Mourón S, Tress M, Gómez-López G, Morente M, Ciruelos E, Rubio-Camarillo M, Rodriguez-Peralto JL, Pujana MA, Pisano DG, Quintela-Fandino M. Manso L, et al. Among authors: mouron s. PLoS One. 2016 May 19;11(5):e0155840. doi: 10.1371/journal.pone.0155840. eCollection 2016. PLoS One. 2016. PMID: 27195705 Free PMC article.
Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics.
Navarro P, Bueno MJ, Zagorac I, Mondejar T, Sanchez J, Mourón S, Muñoz J, Gómez-López G, Jimenez-Renard V, Mulero F, Chandel NS, Quintela-Fandino M. Navarro P, et al. Among authors: mouron s. Cell Rep. 2016 Jun 21;15(12):2705-18. doi: 10.1016/j.celrep.2016.05.052. Epub 2016 Jun 9. Cell Rep. 2016. PMID: 27292634 Free article.
Critically short telomeres and toxicity of chemotherapy in early breast cancer.
Quintela-Fandino M, Soberon N, Lluch A, Manso L, Calvo I, Cortes J, Moreno-Antón F, Gil-Gil M, Martinez-Jánez N, Gonzalez-Martin A, Adrover E, de Andres R, Viñas G, Llombart-Cussac A, Alba E, Mouron S, Guerra J, Bermejo B, Zamora E, García-Saenz JA, Simon SP, Carrasco E, Escudero MJ, Campo R, Colomer R, Blasco MA. Quintela-Fandino M, et al. Among authors: mouron s. Oncotarget. 2017 Mar 28;8(13):21472-21482. doi: 10.18632/oncotarget.15592. Oncotarget. 2017. PMID: 28423524 Free PMC article. Clinical Trial.
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer.
Zagorac I, Fernandez-Gaitero S, Penning R, Post H, Bueno MJ, Mouron S, Manso L, Morente MM, Alonso S, Serra V, Muñoz J, Gómez-López G, Lopez-Acosta JF, Jimenez-Renard V, Gris-Oliver A, Al-Shahrour F, Piñeiro-Yañez E, Montoya-Suarez JL, Apala JV, Moreno-Torres A, Colomer R, Dopazo A, Heck AJR, Altelaar M, Quintela-Fandino M. Zagorac I, et al. Among authors: mouron s. Nat Commun. 2018 Aug 29;9(1):3501. doi: 10.1038/s41467-018-05742-z. Nat Commun. 2018. PMID: 30158526 Free PMC article.
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
Quintela-Fandino M, Apala JV, Malon D, Mouron S, Hornedo J, Gonzalez-Cortijo L, Colomer R, Guerra J. Quintela-Fandino M, et al. Among authors: mouron s. Breast Cancer Res. 2019 May 24;21(1):69. doi: 10.1186/s13058-019-1152-x. Breast Cancer Res. 2019. PMID: 31126332 Free PMC article. Clinical Trial.
Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer.
Quintela-Fandino M, Morales S, Cortés-Salgado A, Manso L, Apala JV, Muñoz M, Gasol Cudos A, Salla Fortuny J, Gion M, Lopez-Alonso A, Cortés J, Guerra J, Malón D, Caleiras E, Mulero F, Mouron S. Quintela-Fandino M, et al. Among authors: mouron s. Clin Cancer Res. 2020 Jan 1;26(1):35-45. doi: 10.1158/1078-0432.CCR-19-2023. Epub 2019 Oct 9. Clin Cancer Res. 2020. PMID: 31597662 Clinical Trial.
42 results